Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
39.77
+0.24 (0.61%)
At close: Sep 3, 2025, 4:00 PM
39.58
-0.19 (-0.48%)
Pre-market: Sep 4, 2025, 7:13 AM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
The 13 analysts that cover Revolution Medicines stock have a consensus rating of "Strong Buy" and an average price target of $69.85, which forecasts a 75.63% increase in the stock price over the next year. The lowest target is $56 and the highest is $82.
Price Target: $69.85 (+75.63%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 7 | 8 | 7 |
| Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $75 | Buy | Initiates | $75 | +88.58% | Aug 19, 2025 |
| Needham | Needham | Strong Buy Maintains $57 → $56 | Strong Buy | Maintains | $57 → $56 | +40.81% | Aug 7, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +63.44% | Jul 15, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +101.16% | Jun 25, 2025 |
| Needham | Needham | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +43.32% | Jun 24, 2025 |
Financial Forecast
Revenue This Year
6.46M
Revenue Next Year
31.52M
from 6.46M
Increased by 387.56%
EPS This Year
-5.34
from -3.58
EPS Next Year
-5.88
from -5.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 43.8M | 149.6M | |||
| Avg | 6.5M | 31.5M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,214.8% | |||
| Avg | - | 387.6% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.95 | -4.39 | |||
| Avg | -5.34 | -5.88 | |||
| Low | -5.49 | -7.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.